二肽肽酶 4 (DPP-4) 抑制剂市场 - 增长、趋势、COVID-19 影响和预测 (2022 - 2027)

市场按药物(Januvia、Onglyza/Kombiglyze、Tradjenta、Nesina、Galvus 等)和地理位置细分

市场快照

Dipeptide Peptidase 4 (DPP-4) inhibitors Market Overview
Study Period: 2016-2027
Base Year: 2021
Fastest Growing Market: Latin America
Largest Market: North America
CAGR: 0 %
Dipeptide Peptidase 4 (DPP-4) inhibitors Market Key Players

Need a report that reflects how COVID-19 has impacted this market and its growth?

市场概况

2018 年全球 DPP-4 抑制剂市场价值 105 亿美元,预计 2019-2024 年复合年增长率为 4%。所研究市场的北美 DPP-4 药物部分在 2018 年的收入最高,预计拉丁美洲在预测期内的复合年增长率最高,约为 6%。

  • 在预测期内,增加 2 型糖尿病和肥胖人口将推动市场的增长。
  • DPP-4药物临床试验的增加也将推动预测期内的市场增长。

报告范围

DPP-4抑制剂市​​场按品牌细分,涵盖以下品牌:Januvia、Onglyza/Kombiglyze、Tradjenta、Nesina、Galvus等品牌。该报告分为五个区域:北美、亚太地区、中东和非洲、拉丁美洲和欧洲。

按药物 西格列汀 雅努维亚
沙格列汀 Onglyza/Kombiglyze
利格列汀 永恒的
阿格列汀 不 
维格列汀 加尔维斯
其他 其他 DPP-4
按地区 北美

美国
加拿大
北美其他地区

欧洲

英国
德国
法国
俄罗斯
西班牙
意大利
欧洲其他地区

亚太

澳大利亚
中国
印度
印度尼西亚
日本
马来西亚
菲律宾
韩国
泰国
越南
亚太其他地区

拉丁美洲

巴西
墨西哥
拉丁美洲其他地区

中东和非洲

沙特阿拉伯
南非
伊朗
埃及
阿曼
中东和非洲其他地区

Report scope can be customized per your requirements. Click here.

主要市场趋势

Tradjenta 市场在预测期内将超过默克的 Januvia

在 2019-2024 年的预测期内,全球 Tradjenta 市场的复合年增长率预计为 5.7%,并有望超过 Januvia 市场,后者在 2018 年占据最大市场份额。Tradjenta 市场包括其组合 Jentadueto 和 Jentadueto XR,利格列汀(Tradjenta)和盐酸二甲双胍的组合,用于治疗 2 型糖尿病。2 型糖尿病药物 Tradjenta(利格列汀)并未在德国上市,原因是该县的报销机构做出了一项决定,该决定认为与已经上市的药物相比,它不会提供任何额外的好处。

Dipeptide Peptidase 4 (DPP-4) inhibitors Market Key Trends

北美市场占有率最高

  • 北美在全球 DPP-4 市场占有 38% 的市场份额,其次是亚太地区。预计成熟国家和新兴国家糖尿病患病率的增加将推动市场。多年来,这种增长是由于个人层面因素的整体影响,如人口中位年龄的增加和健康因素,包括人们的肥胖和不活动水平。
  • 在日本、意大利、德国和法国等老年人口比例较高的国家,出生率的降低以及预期寿命的延长预计将推动市场的增长。
Dipeptide Peptidase 4 (DPP-4) inhibitors Market Growth by Region

竞争格局

默克在 2018 年在 DPP-4 市场占有最高的市场份额,预计将保持其地位至 2022 年。此后,由于预计在 2022 年推出仿制西他列汀,其市场份额可能会下降。

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Drivers

    3. 4.3 Restraints

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Bargaining Power of Suppliers

      2. 4.4.2 Bargaining Power of Consumers

      3. 4.4.3 Threat of New Entrants

      4. 4.4.4 Threat of Substitute Products and Services

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Drug

      1. 5.1.1 Dipeptidyl Peptidase - 4 (DPP-4) Inhibitors (Value and Volume 2012-2024)

        1. 5.1.1.1 Januvia (Sitagliptin)

        2. 5.1.1.2 Onglyza (Saxagliptin)

        3. 5.1.1.3 Tradjenta (Linagliptin)

        4. 5.1.1.4 Vipidia/Nesina (Alogliptin)

        5. 5.1.1.5 Galvus (Vildagliptin)

    2. 5.2 Geography

      1. 5.2.1 North America

        1. 5.2.1.1 United States (Value and Volume, 2012-2024)

          1. 5.2.1.1.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)

          2. 5.2.1.1.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)

        2. 5.2.1.2 Canada (Value and Volume, 2012-2024)

          1. 5.2.1.2.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)

          2. 5.2.1.2.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)

        3. 5.2.1.3 Rest of North America (Value and Volume, 2012-2024)

          1. 5.2.1.3.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)

          2. 5.2.1.3.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)

      2. 5.2.2 Europe

        1. 5.2.2.1 France (Value and Volume, 2012-2024)

          1. 5.2.2.1.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)

          2. 5.2.2.1.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)

        2. 5.2.2.2 Germany (Value and Volume, 2012-2024)

          1. 5.2.2.2.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)

          2. 5.2.2.2.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)

        3. 5.2.2.3 Italy (Value and Volume, 2012-2024)

          1. 5.2.2.3.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)

          2. 5.2.2.3.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)

        4. 5.2.2.4 Spain (Value and Volume, 2012-2024)

          1. 5.2.2.4.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)

          2. 5.2.2.4.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)

        5. 5.2.2.5 United Kingdom (Value and Volume, 2012-2024)

          1. 5.2.2.5.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)

          2. 5.2.2.5.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)

        6. 5.2.2.6 Russia (Value and Volume, 2012-2024)

          1. 5.2.2.6.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)

          2. 5.2.2.6.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)

        7. 5.2.2.7 Rest of Europe (Value and Volume, 2012-2024)

          1. 5.2.2.7.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)

          2. 5.2.2.7.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)

      3. 5.2.3 Latin America

        1. 5.2.3.1 Mexico (Value and Volume, 2012-2024)

          1. 5.2.3.1.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)

          2. 5.2.3.1.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)

        2. 5.2.3.2 Brazil (Value and Volume, 2012-2024)

          1. 5.2.3.2.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)

          2. 5.2.3.2.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)

        3. 5.2.3.3 Rest of Latin America (Value and Volume, 2012-2024)

          1. 5.2.3.3.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)

          2. 5.2.3.3.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)

      4. 5.2.4 Asia-Pacific

        1. 5.2.4.1 Japan (Value and Volume, 2012-2024)

          1. 5.2.4.1.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)

          2. 5.2.4.1.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)

        2. 5.2.4.2 South Korea (Value and Volume, 2012-2024)

          1. 5.2.4.2.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)

          2. 5.2.4.2.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)

        3. 5.2.4.3 China (Value and Volume, 2012-2024)

          1. 5.2.4.3.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)

          2. 5.2.4.3.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)

        4. 5.2.4.4 India (Value and Volume, 2012-2024)

          1. 5.2.4.4.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)

          2. 5.2.4.4.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)

        5. 5.2.4.5 Australia (Value and Volume, 2012-2024)

          1. 5.2.4.5.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)

          2. 5.2.4.5.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)

        6. 5.2.4.6 Vietnam (Value and Volume, 2012-2024)

          1. 5.2.4.6.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)

          2. 5.2.4.6.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)

        7. 5.2.4.7 Malaysia (Value and Volume, 2012-2024)

          1. 5.2.4.7.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)

          2. 5.2.4.7.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)

        8. 5.2.4.8 Indonesia (Value and Volume, 2012-2024)

          1. 5.2.4.8.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)

          2. 5.2.4.8.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)

        9. 5.2.4.9 Philippines (Value and Volume, 2012-2024)

          1. 5.2.4.9.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)

          2. 5.2.4.9.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)

        10. 5.2.4.10 Thailand (Value and Volume, 2012-2024)

          1. 5.2.4.10.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)

          2. 5.2.4.10.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)

        11. 5.2.4.11 Rest of Asia-Pacific (Value and Volume, 2012-2024)

          1. 5.2.4.11.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)

          2. 5.2.4.11.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)

      5. 5.2.5 Middle East & Africa

        1. 5.2.5.1 Saudi Arabia (Value and Volume, 2012-2024)

          1. 5.2.5.1.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)

          2. 5.2.5.1.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)

        2. 5.2.5.2 Iran (Value and Volume, 2012-2024)

          1. 5.2.5.2.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)

          2. 5.2.5.2.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)

        3. 5.2.5.3 Egypt (Value and Volume, 2012-2024)

          1. 5.2.5.3.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)

          2. 5.2.5.3.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)

        4. 5.2.5.4 Oman (Value and Volume, 2012-2024)

          1. 5.2.5.4.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)

          2. 5.2.5.4.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)

        5. 5.2.5.5 South Africa (Value and Volume, 2012-2024)

          1. 5.2.5.5.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)

          2. 5.2.5.5.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)

        6. 5.2.5.6 Rest of Middle East & Africa (Value and Volume, 2012-2024)

          1. 5.2.5.6.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)

          2. 5.2.5.6.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)

  6. 6. MARKET INDICATORS

    1. 6.1 Type-1 Diabetes Population (2012-2024)

    2. 6.2 Type-2 Diabetes Population (2012-2024)

  7. 7. COMPETITIVE LANDSCAPE

    1. 7.1 Company Profiles

      1. 7.1.1 Merck And Co.

        1. 7.1.1.1 Overview

        2. 7.1.1.2 Products and Strategies

        3. 7.1.1.3 Recent Development

      2. 7.1.2 AstraZeneca

        1. 7.1.2.1 Overview

        2. 7.1.2.2 Products and Strategies

        3. 7.1.2.3 Recent Development

      3. 7.1.3 Bristol Myers Squibb

        1. 7.1.3.1 Overview

        2. 7.1.3.2 Products and Strategies

        3. 7.1.3.3 Recent Development

      4. 7.1.4 Novartis

        1. 7.1.4.1 Overview

        2. 7.1.4.2 Products and Strategies

        3. 7.1.4.3 Recent Development

      5. 7.1.5 Takeda Pharmaceuticals

        1. 7.1.5.1 Overview

        2. 7.1.5.2 Products and Strategies

        3. 7.1.5.3 Recent Development

      6. 7.1.6 Eli Lilly

        1. 7.1.6.1 Overview

        2. 7.1.6.2 Products and Strategies

        3. 7.1.6.3 Recent Development

      7. 7.1.7 Boehringer Ingelheim

        1. 7.1.7.1 Overview

        2. 7.1.7.2 Products and Strategies

        3. 7.1.7.3 Recent Development

    2. *List Not Exhaustive
    3. 7.2 Company Share Analysis

      1. 7.2.1 Merck And Co.

      2. 7.2.2 AstraZeneca

      3. 7.2.3 Takeda Pharmaceuticals

      4. 7.2.4 Novartis

      5. 7.2.5 Eli Lilly & Boehringer Ingelheim

  8. 8. MARKET OPPORTUNITIES AND FUTURE TRENDS

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Dipeptide Peptidase 4 (Dpp-4) Inhibitors Market market is studied from 2016 - 2027.

The Dipeptide Peptidase 4 (Dpp-4) Inhibitors Market is growing at a CAGR of 0% over the next 5 years.

Latin America is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

Merck, AstraZeneca, Eli Lilly are the major companies operating in Dipeptide Peptidase 4 (Dpp-4) Inhibitors Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!